Breaking Down Altimmune, Inc. (ALT) Financial Health: Key Insights for Investors

Breaking Down Altimmune, Inc. (ALT) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Altimmune, Inc. (ALT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Altimmune, Inc. (ALT) Revenue Streams

Revenue Analysis

Altimmune, Inc. (ALT) reported total revenue of $4.2 million for the fiscal year 2023, primarily derived from research and development collaborations and grant income.

Revenue Source Amount ($) Percentage
Research Collaboration 2.7 million 64.3%
Grant Income 1.5 million 35.7%

Revenue growth trends for the past three years:

Year Total Revenue ($) Year-over-Year Growth
2021 3.1 million N/A
2022 3.8 million 22.6%
2023 4.2 million 10.5%

Key revenue characteristics:

  • No product revenue generated as of 2023
  • Revenue primarily from research partnerships
  • Continued focus on clinical-stage pharmaceutical development

Geographic revenue breakdown for 2023:

Region Revenue ($) Percentage
United States 4.0 million 95.2%
International 0.2 million 4.8%



A Deep Dive into Altimmune, Inc. (ALT) Profitability

Profitability Metrics Analysis

The company's financial performance reveals specific profitability metrics for the most recent fiscal year:

Profitability Metric Value
Gross Profit Margin -58.3%
Operating Margin -286.4%
Net Profit Margin -291.7%

Key profitability insights include:

  • Revenue for the fiscal year: $25.4 million
  • Research and development expenses: $98.5 million
  • Total operating expenses: $106.3 million

Operational efficiency metrics demonstrate:

  • Cost of revenues: $14.8 million
  • Selling, general, and administrative expenses: $37.5 million
  • Operating loss: $72.7 million
Comparative Metric Company Performance Industry Average
Return on Equity -76.4% -12.3%
Return on Assets -49.2% -8.7%



Debt vs. Equity: How Altimmune, Inc. (ALT) Finances Its Growth

Debt vs. Equity Structure: Financial Financing Strategy

As of Q4 2023, Altimmune, Inc. demonstrates a specific debt and equity financing approach with the following key financial characteristics:

Debt Metric Amount
Total Long-Term Debt $42.3 million
Total Short-Term Debt $8.7 million
Total Shareholders' Equity $173.6 million
Debt-to-Equity Ratio 0.29

Key financing characteristics include:

  • Current credit rating: B- by Standard & Poor's
  • Most recent equity offering: $75.2 million in December 2023
  • Weighted average interest rate on debt: 6.25%

Debt financing breakdown:

Debt Type Outstanding Balance Maturity
Convertible Notes $35.6 million 2026
Term Loan $15.4 million 2025

Equity financing sources:

  • Common stock outstanding: 33.1 million shares
  • Market capitalization: $218.4 million
  • Public float: 62%



Assessing Altimmune, Inc. (ALT) Liquidity

Liquidity and Solvency Analysis

Examining the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet obligations.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 2.1 1.8
Quick Ratio 1.9 1.6

Working Capital Analysis

Working capital trends demonstrate the following financial characteristics:

  • Working Capital as of December 31, 2023: $45.2 million
  • Working Capital as of December 31, 2022: $38.7 million
  • Year-over-Year Working Capital Growth: 16.8%

Cash Flow Statement Overview

Cash Flow Category 2023 Amount 2022 Amount
Operating Cash Flow -$22.3 million -$18.6 million
Investing Cash Flow -$5.4 million -$4.9 million
Financing Cash Flow $52.1 million $41.5 million

Liquidity Risk Indicators

  • Cash and Cash Equivalents: $87.6 million
  • Short-Term Debt: $12.3 million
  • Cash Burn Rate: $24.7 million annually



Is Altimmune, Inc. (ALT) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of January 2024, the financial valuation metrics for the company reveal critical insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -6.52
Price-to-Book (P/B) Ratio 1.87
Enterprise Value/EBITDA -8.43

Stock price performance reveals the following key trends:

  • 52-week low: $3.12
  • 52-week high: $8.45
  • Current stock price: $5.67

Analyst recommendations provide additional perspective:

Recommendation Number of Analysts
Buy 4
Hold 2
Sell 0

Additional financial indicators:

  • Market Capitalization: $218.5 million
  • Dividend Yield: 0%
  • Average Trading Volume: 387,000 shares



Key Risks Facing Altimmune, Inc. (ALT)

Risk Factors for Company's Financial Health

The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic positioning.

Financial Risk Assessment

Risk Category Potential Impact Magnitude
Cash Burn Rate Quarterly Operating Expenses $22.4 million
Cash Reserves Current Cash Position $89.6 million
Debt Obligations Total Long-Term Debt $37.2 million

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Approval Challenges
  • Intellectual Property Protection
  • Market Competition Intensity

Strategic Risk Landscape

Key strategic risks include:

  • Research and Development Pipeline Volatility
  • Potential Product Development Delays
  • Market Adoption Uncertainties
  • Funding Requirements for Ongoing Research

Financial Risk Metrics

Risk Indicator Current Status Potential Variance
Revenue Volatility ±15.3% Quarterly Projection
R&D Investment $41.7 million Annual Allocation
Market Capitalization Fluctuation ±22.6% Year-to-Date

Regulatory and Compliance Risks

Potential regulatory challenges include complex approval processes and stringent compliance requirements in the pharmaceutical sector.




Future Growth Prospects for Altimmune, Inc. (ALT)

Growth Opportunities

Altimmune, Inc. demonstrates potential growth through strategic product development and market positioning.

Product Pipeline and Innovation

Product Development Stage Potential Market
AdCOVID Vaccine Phase 1/2 Clinical Trials COVID-19 Prevention
HepTcell Preclinical Stage Hepatitis B Treatment

Revenue Growth Projections

  • Research and development expenses: $33.4 million in 2023
  • Cash and cash equivalents: $98.3 million as of September 30, 2023
  • Net loss: $49.6 million for nine months ending September 30, 2023

Strategic Partnerships

Current collaborative research agreements with pharmaceutical research institutions focusing on vaccine development technologies.

Market Expansion Strategies

  • Focus on infectious disease vaccine development
  • Targeting immunotherapy markets
  • Expanding therapeutic vaccine portfolio

Competitive Advantages

Advantage Description
Proprietary Technology Unique vaccine delivery platforms
Research Expertise Specialized immunology research team

DCF model

Altimmune, Inc. (ALT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.